MedTrace Logo

Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens

NCT01801085 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2017-02-02

No results posted yet for this study

Summary

This is a prospective time-and-motion study to document and compare the time used in preparation, dispensing and administration for capecitabine/oxaliplatin (XELOX) versus IV 5-FU/leucovorin/oxaliplatin (FOLFOX4) regimens in colorectal cancer (CRC) patients.

Conditions

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Queen Elizabeth Hospital, Hong Kong

    collaborator OTHER

  • Princess Margaret Hospital, Hong Kong

    collaborator OTHER_GOV

  • Vivian Wing Yan Lee

    lead OTHER

Principal Investigators

  • Vivian WY Lee, PharmD · CUHK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01801085 on ClinicalTrials.gov